Hope for Pulmonary Arterial Hypertension Treatment Found in New Microbiome Research

The article discusses how inflammation contributes to pulmonary arterial hypertension (PAH) and how gut dysbiosis causes immune dysregulation and systemic inflammation by altering circulating microbial metabolites. The study aimed to characterize the gut microbiome and microbial metabolites in patients with PAH. The study found that patients with PAH had proinflammatory gut dysbiosis, which included fewer copies of gut microbial genes that produce anti-inflammatory short-chain fatty acids (SCFAs) and secondary bile acids, as well as lower plasma concentrations of SCFAs and secondary bile acids. Additionally, patients with PAH had an enrichment of species with the microbial genes that encoded the proinflammatory microbial metabolite trimethylamine. These findings suggest that modulation of the gut microbiome could be a potential treatment for PAH.